Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1977 1
1987 3
1988 2
1989 4
1990 2
1991 2
1992 5
1993 2
1994 3
1995 2
1996 4
1997 3
1998 3
1999 2
2000 2
2001 4
2002 9
2003 3
2004 6
2005 11
2006 9
2007 5
2008 8
2009 11
2010 12
2011 11
2012 7
2013 5
2014 7
2015 7
2016 10
2017 10
2018 14
2019 19
2020 31
2021 32
2022 24
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Results by year

Filters applied: . Clear all
Page 1
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Wallentin L, et al. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717846 Free article. Clinical Trial.
RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI] …
RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9 …
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators. Mentz RJ, et al. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26. N Engl J Med. 2023. PMID: 37632463 Clinical Trial.
Death by month 12 occurred in 131 patients (8.6%) in the ferric carboxymaltose group and 158 (10.3%) in the placebo group; a total of 297 and 332 hospitalizations for heart failure, respectively, occurred by month 12; and the mean (SD) change from baseline to 6 months in the 6-mi …
Death by month 12 occurred in 131 patients (8.6%) in the ferric carboxymaltose group and 158 (10.3%) in the placebo group; a total of 297 an …
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200892 Clinical Trial.
The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascul …
The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo g …
Immediate neurophysiological effects of transcranial electrical stimulation.
Liu A, Vöröslakos M, Kronberg G, Henin S, Krause MR, Huang Y, Opitz A, Mehta A, Pack CC, Krekelberg B, Berényi A, Parra LC, Melloni L, Devinsky O, Buzsáki G. Liu A, et al. Nat Commun. 2018 Nov 30;9(1):5092. doi: 10.1038/s41467-018-07233-7. Nat Commun. 2018. PMID: 30504921 Free PMC article. Review.
Treatable traits in the NOVELTY study.
Agustí A, Rapsomaniki E, Beasley R, Hughes R, Müllerová H, Papi A, Pavord ID, van den Berge M, Faner R; NOVELTY Study Investigators. Agustí A, et al. Respirology. 2022 Nov;27(11):929-940. doi: 10.1111/resp.14325. Epub 2022 Jul 21. Respirology. 2022. PMID: 35861464 Free PMC article.

RESULTS: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean SD of 4.6 2.6, 5.4 2.6 and 6.4 2.8 TTs/patient in those with 'asthma', 'COPD' and 'asthma + COPD', respectively (p < 0.0001); (2) there were no large global geograph

RESULTS: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean SD of 4.6 2.6, 5.4 2.6 and 6.4 2.8 …
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.
Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K, Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. Sforzini L, et al. Mol Psychiatry. 2022 Mar;27(3):1286-1299. doi: 10.1038/s41380-021-01381-x. Epub 2021 Dec 15. Mol Psychiatry. 2022. PMID: 34907394 Free PMC article. Review.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascul …
The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in …
Tau Oligomer-Containing Synapse Elimination by Microglia and Astrocytes in Alzheimer Disease.
Taddei RN, Perbet R, Mate de Gerando A, Wiedmer AE, Sanchez-Mico M, Connors Stewart T, Gaona A, Melloni A, Amaral AC, Duff K, Frosch MP, Gómez-Isla T. Taddei RN, et al. JAMA Neurol. 2023 Nov 1;80(11):1209-1221. doi: 10.1001/jamaneurol.2023.3530. JAMA Neurol. 2023. PMID: 37812432
Brains with dementia but not resilient brains had substantial loss of presynaptic (43%), postsynaptic (33%), and colocalized mature synaptic elements (38%) compared with controls and significantly higher percentages of mature synapses internalized by IBA1-positive microglia (mean …
Brains with dementia but not resilient brains had substantial loss of presynaptic (43%), postsynaptic (33%), and colocalized mature synaptic …
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P
Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P& …
Programmable photonic circuits.
Bogaerts W, Pérez D, Capmany J, Miller DAB, Poon J, Englund D, Morichetti F, Melloni A. Bogaerts W, et al. Nature. 2020 Oct;586(7828):207-216. doi: 10.1038/s41586-020-2764-0. Epub 2020 Oct 7. Nature. 2020. PMID: 33028997 Free article. Review.
295 results